Published in Psychopharmacology (Berl) on November 09, 2005
Effect of ambient temperature on the thermoregulatory and locomotor stimulant effects of 4-methylmethcathinone in Wistar and Sprague-Dawley rats. PLoS One (2012) 1.25
Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans. Br J Pharmacol (2012) 1.23
Impact of ambient temperature on hyperthermia induced by (+/-)3,4-methylenedioxymethamphetamine in rhesus macaques. Neuropsychopharmacology (2006) 1.04
Critical role of peripheral vasoconstriction in fatal brain hyperthermia induced by MDMA (Ecstasy) under conditions that mimic human drug use. J Neurosci (2014) 1.04
Changes in ambient temperature differentially alter the thermoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug Alcohol Depend (2012) 1.03
The hidden side of drug action: brain temperature changes induced by neuroactive drugs. Psychopharmacology (Berl) (2012) 1.02
Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol (2008) 1.01
Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys. Drug Alcohol Depend (2005) 1.00
Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology (2008) 0.98
Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques. Neuroscience (2006) 0.97
Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys. Psychopharmacology (Berl) (2007) 0.96
The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives. Br J Pharmacol (2010) 0.96
Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm (Vienna) (2007) 0.95
Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicol Teratol (2012) 0.94
Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. Br J Pharmacol (2012) 0.93
Saturday night fever in ecstasy/MDMA dance clubbers: Heightened body temperature and associated psychobiological changes. Temperature (Austin) (2014) 0.92
Cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of bioenergetic stress in ecstasy users. Neuropsychobiology (2009) 0.90
Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques. Pharmacol Biochem Behav (2007) 0.90
A developmental comparison of the neurobehavioral effects of ecstasy (MDMA). Neurotoxicol Teratol (2006) 0.88
Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. Psychopharmacology (Berl) (2010) 0.86
Molecular pathology of natriuretic peptides in the myocardium with special regard to fatal intoxication, hypothermia, and hyperthermia. Int J Legal Med (2012) 0.85
Δ9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys. Neuroscience (2011) 0.85
Behavioral, thermal and neurochemical effects of acute and chronic 3,4-methylenedioxymethamphetamine ("Ecstasy") self-administration. Behav Brain Res (2009) 0.85
Environmental conditions modulate neurotoxic effects of psychomotor stimulant drugs of abuse. Int Rev Neurobiol (2012) 0.82
Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart. Psychopharmacology (Berl) (2012) 0.81
Development and validation of a disk solid phase extraction and gas chromatography-mass spectrometry method for MDMA, MDA, HMMA, HMA, MDEA, methamphetamine and amphetamine in sweat. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.80
Effects of MDMA on body temperature in humans. Temperature (Austin) (2014) 0.80
State-dependent and environmental modulation of brain hyperthermic effects of psychoactive drugs of abuse. Temperature (Austin) (2014) 0.79
Caffeine promotes dopamine D1 receptor-mediated body temperature, heart rate and behavioural responses to MDMA ('ecstasy'). Psychopharmacology (Berl) (2010) 0.79
Clinical applications of hallucinogens: A review. Exp Clin Psychopharmacol (2016) 0.78
Effect of prenatal methamphetamine administration during gestational days on mice. Iran J Reprod Med (2015) 0.78
Ethanol-MDMA interactions in rats: the importance of interval between repeated treatments in biobehavioral tolerance and sensitization to the combination. Psychopharmacology (Berl) (2007) 0.77
Clinically Relevant Pharmacological Strategies That Reverse MDMA-Induced Brain Hyperthermia Potentiated by Social Interaction. Neuropsychopharmacology (2015) 0.75
Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther (1971) 4.30
The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev (2003) 3.35
Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers. Neuropsychopharmacology (1998) 2.63
Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci (1998) 1.86
Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol Biochem Behav (1991) 1.76
Reduced thermoregulatory null zone in postmenopausal women with hot flashes. Am J Obstet Gynecol (1999) 1.69
Mechanism of cocaine-induced hyperthermia in humans. Ann Intern Med (2002) 1.55
Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther (1999) 1.49
Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits. J Neurosci (2001) 1.42
Drug preference and mood in humans: d-amphetamine. Psychopharmacology (Berl) (1980) 1.25
Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend (2003) 1.24
The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol (1994) 1.24
A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol (2004) 1.17
Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology (Berl) (2003) 1.17
Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res (1990) 1.16
Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav (1995) 1.14
Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study. Psychopharmacology (Berl) (1999) 1.00
Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res (1996) 0.98
Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med (2000) 0.97
Temperature regulation during exercise. Int J Sports Med (1998) 0.96
Effect of beta1- and beta2-adrenergic stimulation on energy expenditure, substrate oxidation, and UCP3 expression in humans. Am J Physiol Endocrinol Metab (2003) 0.93
beta(1)- and beta(2)-Adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men. J Clin Endocrinol Metab (2001) 0.91
MDMA induced hyperthermia: report of a fatality and review of current therapy. Intensive Care Med (1996) 0.90
MDMA induced hyperthermia: a survivor with an initial body temperature of 42.9 degrees C. J Accid Emerg Med (1997) 0.90
Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy") but not by fenfluramine. Psychopharmacology (Berl) (1998) 0.83
Cocaine alters body temperature and behavioral thermoregulatory responses. Neuroreport (1993) 0.83
Bilateral gluteal compartment syndrome after 'ecstasy' hyperpyrexia. J R Soc Med (2000) 0.82
The effect of submaximal exercise on recovery hemodynamics and thermoregulation in men and women. Res Q Exerc Sport (1999) 0.78
Metabolic consequences of drug misuse. Br J Anaesth (2000) 0.75
Establishment of a diazepam preference in human volunteers following a differential-conditioning history of placebo versus diazepam choice. Exp Clin Psychopharmacol (2002) 4.85
Neural substrates for voluntary suppression of negative affect: a functional magnetic resonance imaging study. Biol Psychiatry (2005) 4.84
Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol Psychiatry (2005) 3.35
Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. J Subst Abuse Treat (2010) 1.97
Effects of REM sleep and ambient temperature on hot flash-induced sleep disturbance. Menopause (2006) 1.84
Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol (2002) 1.35
Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend (2003) 1.24
Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology (2003) 1.18
The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) (2006) 1.08
Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla. Neuroreport (2005) 1.03
Real-time fMRI of cortico-limbic brain activity during emotional processing. Neuroreport (2004) 1.02
Comparison of intranasal methamphetamine and d-amphetamine self-administration by humans. Addiction (2012) 1.00
Neural correlates of internally-generated disgust via autobiographical recall: a functional magnetic resonance imaging investigation. Neurosci Lett (2004) 0.99
Cocaine-dependence and cocaine-induced paranoia and mid-latency auditory evoked responses and sensory gating. Psychiatry Res (2006) 0.99
Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology (Berl) (2002) 0.96
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain (2012) 0.95
Linear and non-linear measures indicate gastric dysmotility in patients suffering from acute schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.93
Impact of formulation on the abuse liability, safety and regulation of medications: the expert panel report. Drug Alcohol Depend (2006) 0.91
Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices. Biol Psychiatry (2006) 0.91
Personality and the acute subjective effects of d-amphetamine in humans. J Psychopharmacol (2013) 0.89
Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society. Behav Pharmacol (2010) 0.87
Cardiac effects of MDMA on the metabolic profile determined with 1H-magnetic resonance spectroscopy in the rat. NMR Biomed (2009) 0.87
Cue-induced craving for marijuana in cannabis-dependent adults. Exp Clin Psychopharmacol (2011) 0.84
Lack of a fluoxetine effect on prednisolone disposition and cortisol suppression. Pharmacotherapy (2004) 0.83
Reinforcing effects of diazepam under anxiogenic conditions in individuals with social anxiety. Exp Clin Psychopharmacol (2005) 0.83
Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addict Behav (2013) 0.82
Escitalopram treatment of menopausal hot flashes. Menopause (2011) 0.80
Major depression: the relative contribution of gender, MDMA, and cannabis use. Depress Anxiety (2008) 0.80
Postmarketing surveillance of abuse liability of sibutramine. Drug Alcohol Depend (2003) 0.78
Evoked potential correlates of post-traumatic stress disorder in refugees with history of exposure to torture. J Psychiatr Res (2013) 0.77
Steps physicians report taking to reduce diversion of buprenorphine. Am J Addict (2013) 0.77
What kind of erotic film clips should we use in female sex research? An exploratory study. J Sex Med (2007) 0.76
Risk management and post-marketing surveillance of CNS drugs: an introduction. Drug Alcohol Depend (2009) 0.76
Effects of acute 3,4-methylenedioxymethamphetamine on sleep and daytime sleepiness in MDMA users: a preliminary study. Sleep (2009) 0.75
Significant difference in beat-to-beat QT interval variability among different leads. Heart Dis (2002) 0.75
Behavioral and neurochemical effects of repeated MDMA administration during late adolescence in the rat. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.75